In today’s briefing:
- FnGuide Top 10 Rebalancing: How We Trade Shinhan IN/Celltrion OUT
- Enzychem Lifesciences Corp (183490 KS): Picked New Drug Development as Future Growth Engine
- Diamond Hill Small Cap Fund Q1 2022 Market Commentary
FnGuide Top 10 Rebalancing: How We Trade Shinhan IN/Celltrion OUT
- With the screening period over (May 3-31), Shinhan IN/Celltrion OUT is virtually a foregone conclusion.
- We should consider an individually-hedged approach, instead of a plain long/short, with a tightly moving-together peer, preferably on a single-day trading window.
- I suggest using KB Financial and Celltrion Healthcare as hedges of LONG & SHORT for Shinhan and Celltrion, respectively.
Enzychem Lifesciences Corp (183490 KS): Picked New Drug Development as Future Growth Engine
- Enzychem Lifesciences Corp (183490 KS) is eyeing on its lead innovative drug candidate, EC-18 for long-term sustainable growth driver. EC-18 is in late-stage clinical trial for couple of indications.
- EC-18 is in phase 2 clinical trial for the treatment of chemoradiation-induced oral mucositis (CRIOM), an acute inflammation of the oral mucosa following systemic chemoradiation therapy.
- Currently, CRIOM has no approved therapies. Enzychem Lifesciences has filed for FDA breakthrough therapy designation for EC-18 in CRIOM, which will enable designing of phase 3 study.
Diamond Hill Small Cap Fund Q1 2022 Market Commentary
- Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment.
- Amid a rocky market environment, our portfolio’s negative returns still outpaced the Russell 2000 Index by a healthy margin in Q1.
- After a strong rebound in 2021, global GDP growth is expected to moderate in 2022.
- From current levels, equity market returns over thenext five years are likely to be below historical averages.
Before it’s here, it’s on Smartkarma
